We provide you with 20 years of free, institutional-grade data for SYBX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of SYBX. Explore the full financial landscape of SYBX stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about SYBX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Synlogic, Inc(NASDAQ:SYBX) 
Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase II clinical trial...
Website: http://www.synlogictx.com
Founded: 2014
Full Time Employees: 76
Sector: Healthcare
Industry: Biotechnology